Neuroimmunological Diagnostic Tests

  • Andrew R. Pachner


This chapter discusses diagnostic tests commonly used by neuroimmunologists which are specialized for use in inflammatory and infectious diseases. These are generally assays of the blood or cerebrospinal fluid (CSF), two bodily fluids readily accessible to the clinician. We will not discuss the standard neurological tests performed by neurologists in evaluating neurological disease, such as the history, examination, imaging of the brain by MRI or CT scanning, electroencephalography, electromyography, nerve conduction studies, or evoked responses, which are discussed in Chap. 2. Consistent with its strong link to basic research, much of clinical neuroimmunology is dependent on laboratory assays. Researchers are constantly trying to move assays developed in research laboratories into the clinical arena, albeit with varying degrees of success. As we have discussed concerning the value of surrogate markers of diseases, it is one thing to be able to demonstrate statistically robust sensitivity and specificity of a test for some aspect of disease, but it is another thing entirely to establish the clinical relevance of that finding. This means the clinical neuroimmunologist must have a firm understanding of the laboratory assays used in the field.


West Nile Virus Chronic Fatigue Syndrome Progressive Multifocal Leukoencephalopathy Lyme Disease Progressive Multifocal Leukoencephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295–303.PubMedCrossRefGoogle Scholar
  2. 2.
    Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12. Dec 11–17.PubMedCrossRefGoogle Scholar
  4. 4.
    Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Reiber H. Cerebrospinal fluid–physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998;4(3):99–107.PubMedGoogle Scholar
  6. 6.
    Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62(6):865–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Thwaites GE, Schoeman JF. Update on tuberculosis of the central nervous system: pathogenesis, diagnosis, and treatment. Clin Chest Med. 2009;30(4):745–54. ix.PubMedCrossRefGoogle Scholar
  8. 8.
    Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88.PubMedCrossRefGoogle Scholar
  9. 9.
    Pachner AR, Li L, Lagunoff D. Plasma cells in the central nervous system in the Theiler’s virus model of multiple sclerosis. J Neuroimmunol. 2011;232:35–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Andrew R. Pachner
    • 1
  1. 1.Department of Neurology and Neuroscience New Jersey Medical SchoolUniversity of Medicine and Dentistry of New JerseyNewarkUSA

Personalised recommendations